Quality of life in the long-term treatment and the role of second-generation antipsychotics

Neuroendocrinology Letters

Volumn 28, Issue SUPPL. 1, 2007, Pages 117-133

  Mohr, Pavel ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Bipolar disorder; Quality of life; Schizophrenia; Second generation antipsychotics; Treatment outcome

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; FLUPENTIXOL; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHORIA; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MONOTHERAPY; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34047205507     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Awad AG, Voruganti LNP. New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry. 2004; 49: 297-302.
2. Beasley Jr. CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? J Clin Psychopharmacol. 2006; 26: 40-44.
3. Bergner M. Quality of life, health status and clinical research. Med Care. 1989; 27 (Suppl 3): S148-S156.
4. Bobes J, Gutiérrez M, Gibert J, Gonzáles MP, Herraiz L, Fernández A. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry. 1998; 13: 158-163.
5. Bobes J, García-Portilla MP. Quality of life in schizophrenia. In: Quality of life in mental disorders, 2nd Edition. (Eds. Katschnig H, Freeman H, Sartorius N). John Wiley & Sons Ltd., 2005: 153-168.
6. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, Vagero M, Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005; 66: 111-121.
7. Breier A, Berg PH, Thakore JT, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM. Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. Am J Psychiatry. 2005; 162: 1879-1887.
8. Browne S, Clarke M, Gervin M, Waddington JL, Larkin C, O'Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry. 2000; 176: 173-176.
9. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson F, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005; 162: 1351-1360.
10. Carrick R, Mitchell A, Powell RA, Lloyd K. The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychology and Psychotherapy. 2004; 77: 19-33.
11. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res. 2003; 63: 97-101.
12. de Lima MS, Mari JJ, Breier A, Costa AM, de Sena EP, Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation sntipsychotics. J Clin Psychiatry. 2005; 66: 831-838.
13. Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004; 20: 139-154.
14. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry. 2005; 187: 131-136.
15. Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol. 2005; 19(Suppl. 5): 32-38.
16. Gee L, Pearce E, Jackson M. Quality of life in schizophrenia: a grounded theory approach. Health Qual Life Outcomes. 2003;1: 31.
17. Grainger D, Edgell ET, Andersen SW, Wang J. Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial. Eur Neuropsychopharmacol. 1998; 8 (Suppl. 2): S225-S226.
18. Gureje O, Miels W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hastig H, Andersen S, Crawford AM. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003; 61: 303-314.
19. Hamilton SH, Revicki DA, Genduso LA, Beaskey CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North-American double-blind trial. Neuropsychopharmacology. 1998; 18: 41-49.
20. Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones PB, Ratcliffe M, Breier A. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand. 2005; 111: 220-231.
21. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bul. 1984; 10: 388-398.
22. Hertling I, Phillip M, Dvorak A, Glaser T, Mast O, Beneke M, Ramskogler K, Saletu-Zyhlarz G, Walter H, Lesch OM. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Pharmacopsychiatry. 2003; 47: 37-46.
23. Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Int Clin Psychopharmacol. 2006; 21: 11-20.
24. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004; 65: 932-939.
25. Hogan TP, Awad AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminant validity. Psychol Med. 1983; 13: 177-183.
26. Katschnig H, Freeman H, Sartorius N (Eds). Quality of life in mental disorders, 2nd Edition. John Wiley & Sons Ltd., 2005, 368 pp.
27. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003; 160: 741-748.
28. Kilian R, Dietrich S, Toumi M, Angermeyer MC. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psych Scand. 2004; 110: 108-118.
29. Lehman AF, Ward NC, Linn LS. Chronic mental patients: the quality of life issues. Am J Psychiatry 1982; 139(10): 1271-1276.
30. Lehman AF. Well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry. 1983; 40: 369-373.
31. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder. Clin Drug Invest. 2004; 24: 275-286.
32. McGrath BM, Tempier RP. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey. Pharmacopsychiatry. 2005; 38: 147-157.
33. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes. 2005; 3: 72.
34. Montes JM, Ciudad A, Gascón J, Gómez JC, EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progr Neuro-Psychopharm & Biol Psychiatry. 2003; 27: 667-674.
35. Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry. 1986; 43: 342-346.
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995; 10: 133-138.
37. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kuhn KU, Bender S, Bandelow B, Lemmer W, Moritz S. Dittmann RW. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005; 111: 106-115.
38. Namjoshi MA, Buesching DP. A review of the health-related quality of life literature in bipolar disorde. Qual Life Res. 2001; 10: 105-115.
39. Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE Jr. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord. 2002; 69: 109-118.
40. Namjoshi M, Xu W, Berg PH, Roychowdhury SM, Cavazzoni P, Naber D, Breier A. Olanzapine versus ziprasidone: quality-of-life changes in patients with schizophrenia. J Psychopharmacol. 2003; 17 (Suppl. 3): A50.
41. Nasrallah H, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004; 65: 531-536.
42. Priebe S, Roder-Waner U, Kaiser W. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999; 45: 7-12.
43. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM, Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999; 8: 417-426.
44. Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM; Depakote Comparator Study Group. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry. 2003; 64: 288-294.
45. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, Modai I. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacology. 2002; 12: 31-38.
46. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperdone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: A naturalistic comparative study. J Clin Psychopharmacol. 2004; 24: 582-591.
47. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. A randomized controlled trial. JAMA. 2003; 290: 2693-2702.
48. Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int Clin Psychopharmacol. 2002; 17: 227-237.
49. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004; 26: 125-134.
50. Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK; HGDH Research Group. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005; 78: 161-169.
51. Strejilevich SA. Palatnik A, Avila R, Bustin J, Cassone J, Figueroa S, Gimenez M, de Erausquin GA. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psych Res. 2005; 133: 277-280.
52. Tunis SL, Croghan TW, Heliman DK, Johnstone BM, Obenchain RL. Reliability, validity, and application of the medical outcomes study 36-item Short-Form Health Survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care. 1999; 37: 678-691.
53. Vorungati L, Cortese L, Owyeumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000; 43: 135-145.
54. Vorungati L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002; 57: 201-208.
55. Vorungati LNP, Awad AG. Neuroleptic dysphoria - toward a new synthesis. Psychopharmacology. 2004; 171: 121-132.
56. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
57. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine. 1998; 46: 569-1585.
58. Zhang PL, Santos JM, Newcomer J, Pelfrey B, Johnson MC, de Erausquin GA. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71: 137-144.